TW200700083A - Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer - Google Patents
Anti-ctla4 antibody and indolinone combination therapy for treatment of cancerInfo
- Publication number
- TW200700083A TW200700083A TW095108280A TW95108280A TW200700083A TW 200700083 A TW200700083 A TW 200700083A TW 095108280 A TW095108280 A TW 095108280A TW 95108280 A TW95108280 A TW 95108280A TW 200700083 A TW200700083 A TW 200700083A
- Authority
- TW
- Taiwan
- Prior art keywords
- cancer
- compound
- indolinone
- ctla4 antibody
- ylidene
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical compound C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 abstract 3
- 229960005386 ipilimumab Drugs 0.000 abstract 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical group CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 abstract 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 238000009098 adjuvant therapy Methods 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 229940125904 compound 1 Drugs 0.000 abstract 1
- 229940125782 compound 2 Drugs 0.000 abstract 1
- 229940126214 compound 3 Drugs 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 238000009093 first-line therapy Methods 0.000 abstract 1
- 102000043321 human CTLA4 Human genes 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- LIZNIAKSBJKPQC-GDNBJRDFSA-N n-[2-(ethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide Chemical compound CCNCCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LIZNIAKSBJKPQC-GDNBJRDFSA-N 0.000 abstract 1
- 238000009099 neoadjuvant therapy Methods 0.000 abstract 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 abstract 1
- 238000009094 second-line therapy Methods 0.000 abstract 1
- 238000009095 third-line therapy Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66465305P | 2005-03-23 | 2005-03-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW200700083A true TW200700083A (en) | 2007-01-01 |
Family
ID=36680342
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW095108280A TW200700083A (en) | 2005-03-23 | 2006-03-10 | Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20090074787A1 (enExample) |
| EP (1) | EP1863532A1 (enExample) |
| JP (1) | JP2006265245A (enExample) |
| KR (1) | KR20070104673A (enExample) |
| CN (1) | CN101146553A (enExample) |
| AR (1) | AR054237A1 (enExample) |
| AU (1) | AU2006227880A1 (enExample) |
| BR (1) | BRPI0607579A2 (enExample) |
| CA (1) | CA2602316A1 (enExample) |
| IL (1) | IL185491A0 (enExample) |
| MX (1) | MX2007011767A (enExample) |
| NZ (1) | NZ561138A (enExample) |
| RU (1) | RU2007135167A (enExample) |
| TW (1) | TW200700083A (enExample) |
| WO (1) | WO2006101692A1 (enExample) |
| ZA (1) | ZA200708026B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080040007A (ko) * | 2005-09-20 | 2008-05-07 | 화이자 프로덕츠 인크. | 티로신 키나제 억제제를 이용한 치료의 투여형 및 방법 |
| CA2647282A1 (en) * | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| WO2008083239A2 (en) * | 2006-12-27 | 2008-07-10 | The Johns Hopkins University | Compositions and methods for stimulating an immune response |
| US8119129B2 (en) | 2008-08-01 | 2012-02-21 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases |
| SMT201700293T1 (it) * | 2009-07-20 | 2017-07-18 | Bristol Myers Squibb Co | Combinazione di un anticorpo anti-ctla-4 con etoposide per il trattamento sinergico di malattie proliferative |
| EP2488553B1 (en) * | 2009-10-12 | 2015-06-17 | Pfizer Inc. | Cancer treatment |
| CA3113343C (en) | 2010-06-03 | 2024-10-08 | Pharmacyclics Llc | USE OF BRUTON'S TYROSINE KINASE INHIBITORS IN THE TREATMENT OF FOLLICULAR LYMPHOMA |
| WO2012042421A1 (en) | 2010-09-29 | 2012-04-05 | Pfizer Inc. | Method of treating abnormal cell growth |
| MX360254B (es) | 2011-03-10 | 2018-10-26 | Pfizer | Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer. |
| KR20200075023A (ko) | 2012-05-04 | 2020-06-25 | 화이자 인코포레이티드 | 전립선 관련된 항원 및 백신 기재 면역치료 요법 |
| WO2013173223A1 (en) | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| US10954567B2 (en) | 2012-07-24 | 2021-03-23 | Pharmacyclics Llc | Mutations associated with resistance to inhibitors of Bruton's Tyrosine Kinase (BTK) |
| WO2014182761A1 (en) * | 2013-05-09 | 2014-11-13 | Mayo Foundation For Medical Education And Research | Treating patients based on immune subtypes |
| GB201413665D0 (en) | 2014-07-03 | 2014-09-17 | Transimmune Ag And Yale University | Method for obtaining globally activated monocytes |
| KR101940430B1 (ko) * | 2014-08-07 | 2019-01-18 | 가꼬우호우징 효고 이카다이가쿠 | Il-18과 분자 표적 항체를 병용하는 암 치료약 |
| PT3186281T (pt) | 2014-08-28 | 2019-07-10 | Halozyme Inc | Terapia de combinação com uma enzima de degradação de hialuronano e um inibidor de pontos de verificação imunológica |
| BR112017007765B1 (pt) | 2014-10-14 | 2023-10-03 | Halozyme, Inc | Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo |
| IL292578A (en) * | 2015-02-13 | 2022-06-01 | Sorrento Therapeutics Inc | Antibody therapeutics that bind ctla4 |
| WO2016161347A1 (en) * | 2015-04-03 | 2016-10-06 | Pharmacyclics Llc | Combinations for generating tumor-specific immunological memory |
| ES2879248T3 (es) | 2015-06-24 | 2021-11-22 | Immodulon Therapeutics Ltd | Inhibidor de puntos de control y micobacteria de célula completa para su uso en terapia contra el cáncer |
| US11028155B2 (en) | 2015-09-11 | 2021-06-08 | Nascent Biotech, Inc. | Enhanced delivery of drugs to the brain |
| US11542332B2 (en) | 2016-03-26 | 2023-01-03 | Bioatla, Inc. | Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| TW201803905A (zh) | 2016-06-20 | 2018-02-01 | 克馬伯有限公司 | 用於免疫腫瘤學之多重專一性抗體 |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| US11643463B2 (en) * | 2017-05-19 | 2023-05-09 | Wuxi Biologics (Shanghai) Co., Ltd. | Monoclonal antibodies to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) |
| WO2019148444A1 (en) * | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| IL277095B2 (en) * | 2018-03-07 | 2025-10-01 | Pfizer | Preparations containing anti-PD-1 antibody |
| AU2019301699C1 (en) | 2018-07-11 | 2024-10-10 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| JP7680954B2 (ja) | 2018-12-26 | 2025-05-21 | シティ・オブ・ホープ | 活性化可能なマスクされた抗ｃｔｌａ４結合タンパク質 |
| KR102371980B1 (ko) | 2020-06-29 | 2022-03-08 | 인하대학교 산학협력단 | 췌장암 예방 또는 치료용 조성물 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5844095A (en) * | 1991-06-27 | 1998-12-01 | Bristol-Myers Squibb Company | CTLA4 Ig fusion proteins |
| US5811097A (en) * | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US6051227A (en) * | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) * | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| AU6703198A (en) * | 1997-03-21 | 1998-10-20 | Brigham And Women's Hospital | Immunotherapeutic ctla-4 binding peptides |
| US6682736B1 (en) * | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| US7109003B2 (en) * | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| DK1255752T3 (da) * | 2000-02-15 | 2007-11-26 | Sugen Inc | Pyrrolsubstituerede 2-indolinonproteinkinaseinhibitorer |
| AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| IL149701A0 (en) * | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
| WO2002096361A2 (en) * | 2001-05-30 | 2002-12-05 | Sugen, Inc. | 5-aralkylsulfonyl-3- (pyrrol-2-ylmethylidene)-2-indolinone derivatives as kinase inhibitors |
| US6680306B2 (en) * | 2001-06-21 | 2004-01-20 | Glycogenesys, Inc. | Method for enhancing the effectiveness of cancer therapies |
| WO2004029069A2 (en) * | 2002-09-30 | 2004-04-08 | Pfizer Products Inc. | Hybridomas producing high levels of human sequence antibody |
| AR042042A1 (es) * | 2002-11-15 | 2005-06-08 | Sugen Inc | Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular |
| SI1670785T1 (sl) * | 2003-10-02 | 2010-10-29 | Pharmacia & Upjohn Co Llc | Soli in polimorfi spojine indolinona, substituirani s pirolom |
| US20050182122A1 (en) * | 2003-11-20 | 2005-08-18 | Bello Carlo L. | Method of treating abnormal cell growth using indolinone compounds |
| WO2005092380A2 (en) * | 2004-03-26 | 2005-10-06 | Pfizer Products Inc | Uses of anti-ctla-4 antibodies |
-
2006
- 2006-03-03 KR KR1020077021665A patent/KR20070104673A/ko not_active Ceased
- 2006-03-03 MX MX2007011767A patent/MX2007011767A/es unknown
- 2006-03-03 AU AU2006227880A patent/AU2006227880A1/en not_active Abandoned
- 2006-03-03 CN CNA2006800096169A patent/CN101146553A/zh active Pending
- 2006-03-03 BR BRPI0607579-7A patent/BRPI0607579A2/pt not_active IP Right Cessation
- 2006-03-03 NZ NZ561138A patent/NZ561138A/en not_active IP Right Cessation
- 2006-03-03 EP EP06736897A patent/EP1863532A1/en not_active Withdrawn
- 2006-03-03 WO PCT/US2006/007651 patent/WO2006101692A1/en not_active Ceased
- 2006-03-03 RU RU2007135167/14A patent/RU2007135167A/ru unknown
- 2006-03-03 US US11/817,395 patent/US20090074787A1/en not_active Abandoned
- 2006-03-03 CA CA002602316A patent/CA2602316A1/en not_active Abandoned
- 2006-03-10 AR AR20060100918A patent/AR054237A1/es unknown
- 2006-03-10 TW TW095108280A patent/TW200700083A/zh unknown
- 2006-03-13 JP JP2006068066A patent/JP2006265245A/ja not_active Withdrawn
-
2007
- 2007-08-23 IL IL185491A patent/IL185491A0/en unknown
- 2007-09-18 ZA ZA200708026A patent/ZA200708026B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006227880A1 (en) | 2006-09-28 |
| AR054237A1 (es) | 2007-06-13 |
| CA2602316A1 (en) | 2006-09-28 |
| WO2006101692A1 (en) | 2006-09-28 |
| JP2006265245A (ja) | 2006-10-05 |
| RU2007135167A (ru) | 2009-03-27 |
| CN101146553A (zh) | 2008-03-19 |
| MX2007011767A (es) | 2007-10-18 |
| BRPI0607579A2 (pt) | 2009-09-15 |
| ZA200708026B (en) | 2008-11-26 |
| IL185491A0 (en) | 2008-01-06 |
| EP1863532A1 (en) | 2007-12-12 |
| KR20070104673A (ko) | 2007-10-26 |
| US20090074787A1 (en) | 2009-03-19 |
| NZ561138A (en) | 2009-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW200700083A (en) | Anti-ctla4 antibody and indolinone combination therapy for treatment of cancer | |
| Spitaleri et al. | Phase I/II study of the tumour-targeting human monoclonal antibody–cytokine fusion protein L19-TNF in patients with advanced solid tumours | |
| Nagelkerke et al. | The unfolded protein response as a target for cancer therapy | |
| Li et al. | Effect of Propofol on breast Cancer cell, the immune system, and patient outcome | |
| Ahlskog et al. | In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives | |
| JP2006265245A5 (enExample) | ||
| Shree et al. | Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer | |
| Mahalingam et al. | TRAIL receptor signalling and modulation: Are we on the right TRAIL? | |
| Demizu et al. | Design and synthesis of estrogen receptor degradation inducer based on a protein knockdown strategy | |
| ES2715776T3 (es) | Auristatinas que tienen una unidad de ácido aminobenzoico en el extremo N | |
| Krall et al. | A small‐molecule drug conjugate for the treatment of carbonic anhydrase IX expressing tumors | |
| NO2008019I1 (no) | N-[2-(dietylamino)etyl]-5-[(Z)-(5-fluoro-2-okso-L,2-dihydro-3H-indol-3-yliden)metyl]-2,4-dimetyl-LH-pyrrol-3-karboksamid (sunitinib),samt farmasoeytisk akseptable salter | |
| Yeh et al. | Melatonin as a potential inhibitory agent in head and neck cancer | |
| WO2007113648A3 (en) | Ctla4 antibody combination therapy | |
| GEP20063777B (en) | Crystals Including Malic Acid Salt of N-[2-(Diethylamino) Ethyl]-5-[(5-Fluoro-2-Oxo-3h-Indole-3-Ylidene) Methyl]-2, 4-Dimethyl-1h-Pyrrole-3-Carboxamide, Processes for Its Preparation and Compositions Thereof | |
| SG163583A1 (en) | Anti-ctla-4 antibody and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment | |
| EA201300246A1 (ru) | Ингибиторы тирозинкиназы брутона | |
| AU2014337391B2 (en) | Combination therapies with PSMA ligand conjugates | |
| Liu et al. | Targeting prostate cancer cells with a multivalent PSMA inhibitor-guided streptavidin conjugate | |
| WO2004058171A3 (en) | Antibodies against gpr64 and uses thereof | |
| MX2019005150A (es) | Inhibidores de la tirosina-cinasa de bruton. | |
| PE20091713A1 (es) | Inhibicion del receptor para la proteina estimulante del macrofago (ron), composiciones y metodos | |
| BRPI0713421A2 (pt) | Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero | |
| WO2003105758A3 (en) | Cancer-linked gene as target for chemotherapy | |
| CN114939119A (zh) | 免疫相关和炎性疾病的治疗 |